Phillip Gray, Ph.D.

Director of Assay Development

Dr. Gray joined Ambry in 2007 and currently serves as Director of Assay Development.  Dr. Gray began working with next generation sequencing technologies in 2007 and has expertise on several sequencing platforms and sample preparation/enrichment technologies.  As an early user of these new genomics technologies, he brings a wealth of knowledge and experience to Ambry’s Research and Development team.  Throughout his career, Dr. Gray has held positions at Invitrogen/Life Technologies, Booz Allen Hamilton, and Abbott Molecular.  Dr. Gray received his undergraduate degree in Biology from Georgia State University and received his Ph.D. in Applied Biology from the Georgia Institute of Technology. 

Hsiao-Mei Lu, Ph.D.

Director of Bioinformatics

Dr. Lu received a B.A. from National Chiao Tung University, and a Ph.D. in Bioinformatics from University of Illinois at Chicago. She did her post-doctoral training in the Department of Mathematics and Center for Complex Biological Systems at the University of California, Irvine. Dr. Lu leads a team of scientists, statisticians, and computational biologists in developing next generation sequencing pipelines and variant assessment schemes for clinical diagnostics. Her work has been published in diverse research areas, including allosteric protein communication, protein folding, drug design, and molecular diagnostics. Dr. Lu brings more than ten years of experience in developing algorithms for scientific computing with mathematical modeling, machine learning, data mining, and parallel computing techniques to Ambry.

Felicia Hernandez, Ph.D.

R&D Scientist

Dr. Hernandez received her undergraduate degree in Microbiology and Molecular Genetics from the University of California, Los Angeles and went on to do her Ph.D. training in the Department of Microbiology and Molecular Genetics at the University of California, Irvine. Her thesis involved the development of novel assays to elucidate the dynamic protein-protein interactions that occur during herpes simplex virus type 1 infection and to probe an important structural property of a key regulatory protein necessary for viral replication.  Dr. Hernandez conducted her postdoctoral training in the Department of Immunology and Microbial Science at The Scripps Research Institute in La Jolla, CA, where she studied a new class of anti-viral drugs, which target a cellular host factor and are effective at inhibiting hepatitis C virus replication.  

Hansook Chong, Ph.D.

R&D Scientist

Dr. Chong joined Ambry Genetics in July 2010 as an R&D scientist. She graduated from the University of California, Los Angeles with a B.S. in Biochemistry and received her Ph.D. in Molecular Biology and Biochemistry from the University of California, Irvine (UCI). As a recipient of the NIH Bioinformatics Training Grant and a student of the Institute of Genomics and Bioinformatics at UCI, Dr. Chong specialized in bioinformatics. Her research has focused on genome-wide analyses of nuclear receptor FXR and proteins regulating cholesterol and fatty acid synthesis. Dr. Chong has been active in molecular genetics research for more than six years and has published numerous scientific articles on the genetics of fatty acid and cholesterol regulation, as well as NextGen sequencing analysis methods. 

Xin Wang, Ph.D.

Clinical Laboratory

Before joining Ambry in 2012, Dr. Wang did cancer research at City of Hope Medical Center in Los Angeles (2004-2012). Prior to that he worked as research scientist at Novartis Pharmaceuticals in New Jersey (1998-2004). Dr. Wang received his PhD in biomedical science from University of Montreal, Canada. His research experience covered various areas in transplantation immunology, inflammatory diseases, drug resistance in cancer, cell signaling and biomarker research. His extensive research experience gave him a unique perspective on the importance of personalized medicine and became his motivation to move into molecular diagnostics.

Suzette Farber-Katz, Ph.D.

Scientist I

Dr. Farber-Katz received her B.S. degree in Human Biology and M.S. degree in Biology from the University of California, San Diego (UCSD). She went on to complete her Ph.D. in the department of Biomedical Sciences at UCSD. During her training there, she discovered a novel pathway that explains why certain cancer patients might not respond to chemotherapy agents. Dr. Farber-Katz received an NIH Ruth L. Kirschstein National Research Service Award for her postdoctoral training at the La Jolla Institute for Allergy and Immunology, where she studied novel components of calcium signaling. Dr. Farber-Katz has published articles in several top-tier journals, including two in Cell, and she brings extensive experience in molecular and cell biology and assay development to Ambry.